Study of V116 Pneumococcal Vaccine in Older Adults
Merck & Co., Inc.
2024
n=717
publication
Evidence: high
Scott Paul, Haranaka Miwa, Choi Jung Hyun, Stacey Helen, Dionne Marc, Greenberg David, Grijalva Carlos G, Orenstein Walter A, Fernsler Doreen, Gallagher Nancy, Zeng Tiantian, Li Jianing, Platt Heather L, Chapman Timothy J, Davis Karyn, Dionne Marc, Dzongowski Peter, Girard Ginette, Tellier Guy, Tytus Richard, Jaffuel Sylvain, Nicolas Jean-Francois, Ami Eytan Ben, Bendayan Daniele, Caraco Yoseph, Chowers Michal, Darawsha Mahmud, Peer Avivit, Blasi Francesco Bruno, Castagna Antonella, Costantino Claudio, Martinelli Domenico, Haranaka Miwa, Yono Makoto, Choi Jung Hyun, Choi Won Suk, Lee Dong-Gun, Lee Jacob, Shi Hyejin, Song Joon Young, De luiz Martinez Gustavo, Echave-Sustaeta Maria-Tome Jose Maria, Aumatell Cristina Masuet, Perez Silvia Narejos, Vilella i Morato Anna, Huang Kuo-Chin, Yang Yi-Ching, Butuk David J, Cardona Jose Francisco, Daboul Nizar, Fiel Thomas, Fraser Neil J, Freeman George Hartley, Geller Steven A, Harper Charles Harold, Johnston William Henry Jr., Lenzmeier Thomas C, Pelayo Enrique, Porterfield Laura, Rigonan Kathryn R, Rosen Jeffrey Bruce, Stacey Helen L
Title
Study of V116 Pneumococcal Vaccine in Older Adults
Hypothesis
Does the V116 vaccine provide safety, tolerability, and immunogenicity in pneumococcal vaccine-experienced adults aged 50 and older?
Conclusion
V116 is well tolerated and generates immune responses to all vaccine serotypes in adults previously vaccinated with pneumococcal vaccines.